Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This Study evaluates the possible drug interaction between FosD and verapamil when taken together.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Verapamil

Criteria

Inclusion Criteria:

• Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive.

• Females must be of non-childbearing potential

Exclusion Criteria:

• History of clinically significant disease or disorder or presence of GI, hepatic or renal disease

• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the drug

• Any clinically significant abnormalities in lab safety tests or vital signs as results as judged by the Investigator

• Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product

• Current smokers or use of nicotine products within 1 month prior to enrollment